Dupilumab for children

Open procedure pursuant to Section 105 (1) (a) of the Public Procurement Act for the conclusion of a framework agreement for the procurement of active ingredients subject to itemized settlement, with the possibility of extending the active period of the Framework Agreement. Part 1: Dupilumab for children (OENO:06126) Base quantity: 715,200 mg Option quantity: 238,400 mg Minimum mandatory price rebate quantity for the base quantity: 1,200 mg Minimum mandatory price rebate quantity for the option quantity: 400 mg In the procedure, the Contracting Authority intends to use the option provided for in Section 6 (1) of Government Decree 16/2012 (II. 16.), thus the Contracting Authority stipulates the obligation to provide price rebates exceeding the framework quantity, in such a way that it is divisible by the size of the smallest packaging unit of the given medicine, resulting in a positive integer (mandatory rebate). In addition to the mandatory rebate, tenderers may offer further rebates at their discretion. The Contracting Authority draws attention to the fact that the name, strength, packaging, and administration form of the medicine (product, preparation) offered by the tenderer constitute a professional offer, and therefore cannot be supplemented or modified! On the day of the tender submission deadline, the offered medicine must: - have a marketing authorization in the official register of the National Public Health and Pharmacy Center, and - be validly included in the PUPHA database containing medicines accepted for social security (TB) support by the National Health Insurance Fund on the day of the tender submission deadline, and - the offered medicine must be validly included in the PUPHA database at the latest when the Framework Agreement is concluded (in detail: KD). The tenderer must be included in the register of medicine wholesalers on the day of the tender submission deadline. The tenderer must also have the authorization to distribute the product(s), so if the tenderer is not the holder of the marketing authorization, a declaration of distribution authorization from the authorized party must also be submitted as part of the offer (in detail: KD). Further condition for valid tender submission: registration in the electronic itemized reporting system according to Section 2/E (1) of Government Decree 9/1993 (IV. 2.) NM by the deadline for submission of tenders, as described in KD. Condition for contract award: the winning tenderer must obtain successful qualification in the online reporting system as detailed in KD. The electronic system can be found at: https:\teteles.neak.gov.hu. Detailed rules are contained in KD. The warranty (expiration) period of the medicine is the period specified in the law or official permit. The winning tenderer contracting as a seller must ensure that the expiration date of the medicine extends for at least 12 months from each delivery, with the proviso that if the expiration date of the medicine is less than 12 months at the time of delivery, the unused medicine within the expiration period will be replaced with a medicine with an expiration date of at least 12 months, no later than 1 month before the expiration date. The Contracting Authority draws the attention of economic operators to the fact that, pursuant to Section 73 (1) (j) of the Public Procurement Act, an offer is invalid if it contains a total offer price higher than the product of the unit price per mg (or per ampoule in Part 5) calculated from the net wholesale price of the cheapest medicine containing the given active ingredient among those offered by the tenderer in the respective part, as listed in the PUPHA database on the day of the tender submission, and the total framework quantity.